JP2019502741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502741A5 JP2019502741A5 JP2018538604A JP2018538604A JP2019502741A5 JP 2019502741 A5 JP2019502741 A5 JP 2019502741A5 JP 2018538604 A JP2018538604 A JP 2018538604A JP 2018538604 A JP2018538604 A JP 2018538604A JP 2019502741 A5 JP2019502741 A5 JP 2019502741A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 9
- 208000021039 metastatic melanoma Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022034549A JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281962P | 2016-01-22 | 2016-01-22 | |
| US62/281,962 | 2016-01-22 | ||
| PCT/US2017/014578 WO2017127811A1 (en) | 2016-01-22 | 2017-01-23 | Methods for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034549A Division JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019502741A JP2019502741A (ja) | 2019-01-31 |
| JP2019502741A5 true JP2019502741A5 (https=) | 2020-12-24 |
Family
ID=59362109
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538604A Pending JP2019502741A (ja) | 2016-01-22 | 2017-01-23 | がんを処置するための方法 |
| JP2022034549A Abandoned JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034549A Abandoned JP2022082565A (ja) | 2016-01-22 | 2022-03-07 | がんを処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190030023A1 (https=) |
| EP (1) | EP3405203A4 (https=) |
| JP (2) | JP2019502741A (https=) |
| CN (1) | CN108883132A (https=) |
| CA (1) | CA3010617A1 (https=) |
| WO (1) | WO2017127811A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| JP2020525427A (ja) * | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| MA52789A (fr) * | 2018-02-13 | 2021-04-14 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti-pd-1 |
| JP2021521439A (ja) * | 2018-04-13 | 2021-08-26 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3878446A1 (en) * | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007130373A2 (en) * | 2006-05-01 | 2007-11-15 | Capricorn Pharma, Inc. | Novel triptan formulations and methods for making them |
| CN101466376A (zh) * | 2006-06-12 | 2009-06-24 | 辉瑞产品公司 | 用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂 |
| CA2706292A1 (en) * | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| AU2014228405B2 (en) * | 2013-03-15 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| KR20160093012A (ko) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| NZ724368A (en) * | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| DK3169341T3 (da) * | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| EP3307778A1 (en) * | 2015-06-12 | 2018-04-18 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN109069426B (zh) * | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
-
2017
- 2017-01-23 CA CA3010617A patent/CA3010617A1/en active Pending
- 2017-01-23 CN CN201780007245.9A patent/CN108883132A/zh active Pending
- 2017-01-23 US US16/070,991 patent/US20190030023A1/en not_active Abandoned
- 2017-01-23 EP EP17742110.4A patent/EP3405203A4/en not_active Withdrawn
- 2017-01-23 WO PCT/US2017/014578 patent/WO2017127811A1/en not_active Ceased
- 2017-01-23 JP JP2018538604A patent/JP2019502741A/ja active Pending
-
2022
- 2022-03-07 JP JP2022034549A patent/JP2022082565A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502741A5 (https=) | ||
| JP2019510785A5 (https=) | ||
| Löhr et al. | A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| Tabchi et al. | Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab | |
| JP2012522837A5 (https=) | ||
| ES2904365T3 (es) | Administración conjunta de esteroides y ácido zoledrónico para prevenir y tratar la osteoartritis | |
| CN111278810A (zh) | Atp合酶反向模式的治疗性调节剂 | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2012533595A5 (https=) | ||
| US20210353648A1 (en) | Grapiprant unit dosage forms | |
| Kim et al. | Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer | |
| Sirachainan et al. | Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy | |
| FI3777842T3 (fi) | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi | |
| JP2019533672A5 (https=) | ||
| Xie et al. | Pilot postoperative ileus study of escin in cancer patients after colorectal surgery | |
| ES2644237T3 (es) | Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
| AU2015242786B2 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP2015515971A5 (https=) | ||
| TW201834650A (zh) | 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途 | |
| Shariff | Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis | |
| Ferslew et al. | P-177 safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Jak inhibitor TD-1473 after single and multiple oral doses in healthy subjects |